NSE · Healthcare · Diagnostics & Research
EPS came in at 3.78 against a street estimate of 2.04 — a beat of 85.3%.
with an average price target of ₹501.88.
MIXED New CEO appointed; FY27 transition year with single-digit revenue decline guidance due to loss of major Zoetis contract. Focusing on CDMO, AI-led discovery, and clinical trials. Mid-20% EBITDA margin guided; recovery expected FY28 onwards. Q1 FY27 Clinical trials hindered by slow Indian regulatory approvals for first-in-human and Phase I/II; using international partnerships to accelerate. Bayview in U.S. benefits from Biosecure Act tariff shifts. Analysts pressed on Zoetis revenue gap fill timeline, CDMO pipeline visibility (Bayview/Stelis traction), and margin recovery mechanics. Management emphasized H2 momentum, deliberate exit from low-margin work, and need for one quarter to provide quantified FY28+ guidance. 2026-07-30…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Syngene International Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.